Laboratory evaluation shows NADPH treatment enhances post-stroke recovery in rodents, suggesting therapeutic potential.
Introduction: m 6 A methylation is the most pronounced epitranscriptomic modification of RNAs. Fat mass and obesity-associated (FTO) demethylates m 6 A-modified RNAs. Stroke reduces cerebral FTO expression, leading to increased abundance of m 6 A hypermethylated RNAs. FTO overexpression with a viral vector demethylates m 6 A-modified RNAs and improves post-stroke functional recovery. As NADPH is a potent activator of FTO, we currently evaluated its therapeutic potential in a rodent stroke model. Material and Methods: Mice (adult/aged; male/female) were subjected to transient middle artery occlusion (MCAO) or photothrombotic ischemia, followed by intravenous NADPH treatment. FTO activity and m 6 A RNA methylation were measured using enzymatic assays. NADPH efficacy and therapeutic window were assessed using a battery of sensorimotor and cognitive tests. Brain infarct volume, atrophy, and white matter damage were evaluated using MRI and histology. Results: Post-stroke NADPH administration increased demethylase activity and reduced m 6 A-methylated RNA abundance without altering FTO expression. NADPH treatment promoted significant protection of grey and white matter, and better motor and cognitive recovery in both sexes, with a good therapeutic window and a low minimal efficacious dose. More importantly, FTO was also neuroprotective in aged mice subjected to stroke. Conclusion: NADPH promotes FTO-mediated m 6 A demethylation after stroke, leading to reduced brain damage and enhanced functional recovery in both sexes.
No takes yet. Share an insight, caveat, or question.
Vemuganti et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: